108. TNF receptor-associated periodic syndrome Disease details / Clinical trials / Drug dev / DR info

Clinical trials : 5 /  Drugs : 5 - (DrugBank : 1) / Drug target gene : 1 - Drug target pathways : 43

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
ACZ885
   NOVARTIS FARMA
      2010   -   EUCTR2010-020061-24-IT   Ireland;Italy;United Kingdom
   Novartis Pharma Services AG
      2010   -   EUCTR2010-020061-24-IE   Ireland;Italy;United Kingdom
      2010   Phase 2   EUCTR2010-020061-24-GB   Ireland;Italy;United Kingdom
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
ACZ885D
   NOVARTIS FARMA
      2010   -   EUCTR2010-020061-24-IT   Ireland;Italy;United Kingdom
Canakinumab
   NOVARTIS FARMA
      2010   -   EUCTR2010-020061-24-IT   Ireland;Italy;United Kingdom
   Novartis Pharma Services AG
      2010   -   EUCTR2010-020061-24-IE   Ireland;Italy;United Kingdom
      2010   Phase 2   EUCTR2010-020061-24-GB   Ireland;Italy;United Kingdom
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
Ilaris
   Novartis Pharma Services AG
      2010   -   EUCTR2010-020061-24-IE   Ireland;Italy;United Kingdom
      2010   Phase 2   EUCTR2010-020061-24-GB   Ireland;Italy;United Kingdom
   Novartis Pharmaceuticals
      2025   -   NCT06838143   -
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
Recombinant human monoclonal antibody TO human IL-1beta OF THE IGG1/K class
   Novartis Pharma Services AG
      2010   -   EUCTR2010-020061-24-IE   Ireland;Italy;United Kingdom
      2010   Phase 2   EUCTR2010-020061-24-GB   Ireland;Italy;United Kingdom